J. Cutan. Immunol. Allergy
Journal of Cutaneous Immunology and Allergy
J. Cutan. Immunol. Allergy
2574-4593
Frontiers Media S.A.
16328
10.3389/jcia.2026.16328
Correction
Corrigendum: The possible effectiveness of difamilast in improving barrier dysfunction in patients with atopic dermatitis and in mouse model
Uchiyama et al.
10.3389/jcia.2026.16328
Uchiyama
Akihiko
1
*
Taivanbat
Bayarmaa
1
Kosaka
Keiji
1
Ishikawa
Mai
1
Uehara
Akihito
2
Shimaoka
Masatoshi
3
Ryuzaki
Keiichiro
4
Motegi
Sei-Ichiro
1
1
Department of Dermatology, Gunma University Graduate School of Medicine , Maebashi , Gunma , Japan
2
Department of Dermatology, Saint Pierre Hospital , Takasaki , Gunma , Japan
3
Department of Dermatology, Fujioka General Hospital , Fujioka , Gunma , Japan
4
Department of Dermatology, Gunma Central Hospital , Maebashi , Gunma , Japan
* Correspondence: Akihiko Uchiyama, akihiko1016@gunma-u.ac.jp
20
02
2026
2026
9
16328
30
01
2026
04
02
2026
Copyright © 2026 Uchiyama, Taivanbat, Kosaka, Ishikawa, Uehara, Shimaoka, Ryuzaki and Motegi.
2026
Uchiyama, Taivanbat, Kosaka, Ishikawa, Uehara, Shimaoka, Ryuzaki and Motegi
https://creativecommons.org/licenses/by/4.0/
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on The possible effectiveness of difamilast in improving barrier dysfunction in patients with atopic dermatitis and in mouse model by Uchiyama A, Taivanbat B, Kosaka K, Ishikawa M, Uehara A, Shimaoka M, Ryuzaki K and Motegi S-I (2025). J. Cutan. Immunol. Allergy 8:15151. doi: 10.3389/jcia.2025.15151
retrospective study
atopic dermatitis
Japanese
difamilast
barrier dysfunction
In the original article, there was a mistake in the legend for Figure 1 as published. “(B) Representative images of skin manifestation at day 7 in mice treated with MC903 and treated with vaseline or 1% difamilast.” The correct legend appears below.
“(B) Representative clinical skin manifestation at 0 week (before) and 1 week (after) in patients with AD treated with 1% difamilast.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.